Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the first patient dosed in its Phase 1 dose ...

The development of prodrugs — chemically modified versions of pharmacologically active agents that must undergo transformationin vivoto release the active drug — is a well-established strategy ...

The updated ICH E6 (R3) Good Clinical Practice guidelines are here - discover what's changed and how clinical trials will need to adapt. This in-depth post unravels the key impacts of E6 (R3).